| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we developed a rapid system for the isolation of TCR-like antibodies targeting cancer stem cells by applying our original high-throughput acquisition technology of antigen-specific antibody from single plasma cells. In order to develop radical curative therapy for cancer, it is strongly required to obtain TCR-like antibodies that recognize antigens that selectively express in both cancer cells and cancer stem cells. In this study, we selected antigens whose expression is also found in cancer stem cells from known cancer antigens, and have succeeded to obtain antibodies recognizing a complex of MHC class I and a tumor antigen-peptide (pMHC) with high affinity and specificity.
|
